4.7 Article

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

Journal

BLOOD
Volume 111, Issue 7, Pages 3635-3643

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2007-11-123141

Keywords

-

Categories

Funding

  1. NCI NIH HHS [R01 CA085721-01, R01 CA097085-10, R01 CA097085-01, CA85721, R01 CA085721-07A2, R01 CA085721-02, R01 CA097085-04, R01 CA097085, R01 CA085721-11, R01 CA097085-08, CA113341, R01 CA085721-04, R01 CA097085-02, R01 CA097085-07, R01 CA097085-06, R01 CA085721, CA97085, R01 CA085721-05, R01 CA085721-06, R01 CA097085-05, R01 CA097085-03, R01 CA085721-10, U19 CA113341, R01 CA085721-09, R01 CA085721-08, R01 CA085721-03, R01 CA097085-09] Funding Source: Medline

Ask authors/readers for more resources

B7-H1 is an immunoglobulin-like immune suppressive molecule broadly detectable on the majority of human and rodent cancers, and its functions have been attributed to delivering an inhibitory signal to its counter-receptor programmed death-1 (PD-1) on T cells. Here we report that B7-H1 on cancer cells receives a signal from PD-1 to rapidly induce resistance against T cell-mediated killing because crippling signaling capacity of B7-H1 but not PD-1 ablates this resistance. Importantly, loss of B7-H1 signaling is accompanied by increased susceptibility to immune-mediated tumoricidal activity. In addition to resistance against T-cell destruction, B7-H1(+) cancer cells also become refractory to apoptosis induced by Fas ligation or the protein kinase inhibitor Staurosporine. Our study reveals a new mechanism by which cancer cells use a receptor on immune cells as a ligand to induce resistance to therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available